Sure…Suven is a key supplier of NCE molecules and drug intermediates to MNC life science and fine chemical majors. This is a high margin business and cannot be easily replicated by competition. The company has announced a capex of Rs 600 crore to modernize and upgrade it’s facilities. Previous investment in Rising pharma has been liquidated at a decent profit.
Lastly, they have demerged their life sciences business which was a drag on overall returns.
| Subscribe To Our Free Newsletter |
